Navigation Links
Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting

Irvine, CA and Annapolis Junction, MD (PRWEB) July 28, 2014

Proove Biosciences, the commercial and research leader in personalized medicine, will be exhibiting data and research conducted through their latest proprietary testing services at this year’s International Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The event will take place July 30th-August 3rd, at the Hyatt Regency, in Orlando, Florida.

The meeting is designed to enhance the knowledge and clinical competence of physicians who care for patients suffering specificity from spine pain. The premier event will focus on the latest evidence-based findings, current research, and the future of the field.

“The International Spine Intervention Society is an industry leading organization dedicated to promoting the latest and most effective options for the treatment of pain from spine injury and disease,” stated Proove Biosciences CEO, Brian Meshkin. “Proove Biosciences has been recognized as a leader in personalized pain medicine and genetic testing, and uses evidence-based research to help physicians and patients better understand and treat their pain.”

Major components of this year’s forum will be emerging and alternative technologies in interventional spine care; how to prepare your practice in using outcome-based medicine and registries; and multiple research presentations.

“We are looking forward to exhibiting and explaining how our research is helping patients better manage and understand their pain, while lowering the associated healthcare costs and increasing prescription efficiency.”

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
2. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
3. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
4. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
7. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
8. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
9. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
10. WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division
11. Sangamo BioSciences Reports Second Quarter 2014 Financial Results
Post Your Comments:
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of ... Israel time, at the law offices of Goldfarb ... Floor, Tel Aviv, Israel . ... Tamir to the Board of Directors; , election of ... of an amendment to certain terms of options granted to our Chief ...
Breaking Biology Technology:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
Breaking Biology News(10 mins):